Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib AND Glivec

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Imatinib AND Glivec. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2012-005696-14 Sponsor Protocol Number: 6451 Start Date*: 2013-09-19
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
    Medical condition: Chronic phase Chronic Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003505-26 Sponsor Protocol Number: AGMT_ALCL1 Start Date*: 2015-03-30
    Sponsor Name:AGMT gemeinnützige GmbH
    Full Title: A “window of opportunity” trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy
    Medical condition: Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10002235 Anaplastic large cell lymphomas T- and-cell types HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000973-40 Sponsor Protocol Number: AB04030 Start Date*: 2008-12-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in...
    Medical condition: gastro-intestinal stromal tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Prohibited by CA) AT (Completed) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000397-30 Sponsor Protocol Number: Ponatinib-3001 Start Date*: 2018-10-23
    Sponsor Name:Millenium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda pharmaceutical Company Limited)
    Full Title: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelp...
    Medical condition: Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080018 Philadelphia positive acute lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FI (Completed) BG (Completed) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005322-68 Sponsor Protocol Number: farm 69j aj9 Start Date*: 2007-10-30
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10042953 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012057-38 Sponsor Protocol Number: CQTI571A2301 Start Date*: 2009-08-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arteria...
    Medical condition: Pulmonary arterial hypertension (PAH) patients who have a PVR ≥800 dynes.sec.cm-5 despite treatment with two or more specific PAH therapies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) FR (Completed) SE (Completed) BE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000233-18 Sponsor Protocol Number: AIO KRK 0205 Start Date*: 2008-04-09
    Sponsor Name:Universität zu Köln
    Full Title: Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom
    Medical condition: fortgeschrittenes kolorektalen Karzinom mit inoperablen Metastasen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010035 Colorectal cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000688-41 Sponsor Protocol Number: IEO S394/108 Start Date*: 2008-10-21
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: IMATINIB MESYLATE IN ADVANCED LOW GRADE SOLID TUMORS EXPRESSING IMATINIB MESYLATE TARGETS
    Medical condition: low grade malignant tumor (ie: solitary fibrous malignant tumor, hemangioendothelioma, myoepithelioma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001784-88 Sponsor Protocol Number: WHO-FIN-COVID-19 Start Date*: 2020-04-29
    Sponsor Name:University of Helsinki
    Full Title: WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19)
    Medical condition: SARS-COV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037373 Pulmonary disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018419-14 Sponsor Protocol Number: CAMN107A2120 Start Date*: 2010-10-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ...
    Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009700 CML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001614-41 Sponsor Protocol Number: CSTI571BIT06 Start Date*: 2005-05-19
    Sponsor Name:NOVARTIS FARMA
    Full Title: OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT
    Medical condition: TREATMENT OF PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT .
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039491 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006185-15 Sponsor Protocol Number: SPIRIT 2 Start Date*: 2008-04-22
    Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust
    Full Title: STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in pati...
    Medical condition: newly-diagnosed chronic-phase Chronic myeloid leukaemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004497-11 Sponsor Protocol Number: P070131 Start Date*: 2008-08-21
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Impact des Inhibiteurs de Tyrosine Kinase sur la fertilité masculine. GLIFERTI
    Medical condition: LMC et GIST traités par un inhibiteur de tyrosine kinase en monothérapie.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021929 Infertilité masculine PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003839-41 Sponsor Protocol Number: HOVON 78 CML Start Date*: 2007-07-19
    Sponsor Name:HOVON Foundation
    Full Title: Imatinib in combination with Cytarabine as compared to Imatinib alone in patients with first chronic phase Chronic Myeloid Leukemia. A prospective randomized phase III study.
    Medical condition: Patients with first chronic phase Chronic Myeloid Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001647-30 Sponsor Protocol Number: ESPHALL Start Date*: 2004-04-28
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)
    Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021344-17 Sponsor Protocol Number: CQTI571A2102 Start Date*: 2011-01-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-admini...
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002658-31 Sponsor Protocol Number: 71/2006/U/Sper Start Date*: 2006-06-08
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.
    Medical condition: PERIPHERAL T-CELL LYMPHOMA PTCL EXPRESSING PDGFRA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025310 Lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021755-34 Sponsor Protocol Number: 2010-021755-34 Start Date*: 2010-07-22
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study on imatinib in combination with RAD001 in advanced chordoma
    Medical condition: PDGFRB and mTOR (or S6 or 4BP1) positive advanced chordoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039492 LLT
    9.1 10006007 PT
    9.1 10039498 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000869-21 Sponsor Protocol Number: Ima-NF1-2012 Start Date*: 2012-04-12
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Pilot study: Imatinib for the treatment of plexiform neurofibromas in NF1 patients.
    Medical condition: Patients with NF1 and plessiform neurofibromas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 02:28:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA